Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Comparison of Continuous Cardiac Rhythm Monitoring and Standard Care in Post-MI Patients With Significant Scar and Reduced LVEF (PRAETORIAN-LUX)

10 de novembro de 2026 atualizado por: Reinoud. E. Knops, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Prospective Randomized Comparison of Standard Care Versus Continuous Cardiac Rhythm Monitoring of Patients With Significant Myocardial Scar and Moderately Reduced Ejection Fraction After Myocardial Infarction

After myocardial infarction (MI), reduced LVEF (≤35%) is a known risk marker for sudden cardiac death (SCD), yet many SCD cases occur with LVEF >35% as myocardial scarring remains a strong arrhythmogenic substrate regardless of preserved function. Non-sustained ventricular tachycardias ((NS)VTs) predict malignant arrhythmias and highlight the importance of early detection.

The primary objective is to determine whether continuous cardiac rhythm monitoring after myocardial infarction improves the detection of cardiac arrhythmias that require medical intervention by conducting a prospective, multi-center, international, randomized trial.

Visão geral do estudo

Status

Recrutamento

Condições

Descrição detalhada

After myocardial infarction (MI), reduced left ventricular ejection fraction (LVEF ≤35%) is a well-known risk factor for sudden cardiac death (SCD), but many SCD cases occur in patients with preserved or mildly reduced LVEF (>35%) due to the arrhythmogenic potential of myocardial scar tissue. Non-sustained ventricular tachycardia (NSVT) is an early marker of malignant arrhythmias, underscoring the value of continuous rhythm monitoring. This prospective, multicentre, randomized trial investigates whether continuous cardiac rhythm monitoring using an implantable loop recorder in post-MI patients with LVEF >35 ≤50% and proven myocardial scar improves detection of clinically relevant arrhythmias compared with standard care. Secondary aims include evaluating the incidence of NSVT/VT/VF, premature ventricular contraction (PVC) burden, and the prognostic value of biomarkers such as NT-proBNP, Lp(a), IL-6, and CRP, as well as assessing patient safety perception and the potential health benefits of early intervention.

Tipo de estudo

Intervencional

Inscrição (Estimado)

256

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Reinoud E Knops, Professor, MD, PhD
  • Número de telefone: +31205666555
  • E-mail: r.e.knops@amc.nl

Estude backup de contato

Locais de estudo

    • North Holland
      • Amsterdam, North Holland, Holanda, 1105
        • Recrutamento
        • Amsterdam Medical Center Amsterdam
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Patients ≥ 18 years of age with a recent (≤ 12 months) STEMI or NSTEMI according to the definition by current ESC/AHA guidelines

  • LVEF >35-≤50% measured > 48 hours after index STEMI or NSTEMI

    o In case a candidate has an LVEF <35% after a recent MI, the responsible physician can decide to treat the patient with GDMT first and reassess the LVEF after 3 months post-MI

  • Clinically relevant myocardial scar, identified by one of the following criteria:

    • Post-MI TTE: Akinetic or dyskinetic myocardial segments seen on two anatomically adjacent echocardiographic segments suggestive for ischemic scar
    • Post-MI ECG: Pathologic Q-waves of ≥0.04 seconds in duration and ≥25% of the R wave amplitude in at least two contiguous leads
    • Post-MI MRI: Late gadolinium enhancement (LGE) in a typical ischemic distribution pattern, characterized by subendocardial or transmural involvement in at least one myocardial segment corresponding to a coronary artery territory, and confirmed on two orthogonal imaging planes
    • Post-MI nuclear imaging: Severely reduced perfusion and absent of metabolic activity in two or more contiguous segments, with tracer uptake less than 50%

Exclusion Criteria:

  • Patients implanted with any CIED or with a guideline indication for a CIED
  • Indication for chronic renal dialysis
  • Patients with life expectancy shorter than 12 months due to any medical condition
  • NYHA Class IV
  • Participation in another trial that may interfere
  • Woman who are pregnant or breast feeding

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Triagem
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Implantable Cardiac Monitor arm

Patients undergoing an ICM implant for continuous cardiac monitoring

Implantable cardiac monitor implantation for continuous monitoring

Sem intervenção: Control group

Control group with standard of care without ICM implant

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Time to first documented cardiac arrhythmia prompting medical intervention
Prazo: Throughout the planned 36-month participant follow-up period.

Composite endpoint defined as the first documented cardiac arrhythmia that prompts a clinical action, including a change in medication, a diagnostic or interventional procedure, or hospitalization. Each participant contributes only their first qualifying event, regardless of arrhythmia type or clinical action. The outcome will be reported as the cumulative incidence of this composite event, expressed as a percentage, and compared between the insertable cardiac monitor (ICM) and standard-care groups using time-to-event analysis.

Throughout the planned 36-month participant follow-up period.

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Number of participants with non-sustained ventricular tachycardia, ventricular tachycardia, or ventricular fibrillation
Prazo: Throughout the planned 36-month participant follow-up period.

Composite endpoint comprising documented non-sustained ventricular tachycardia (NSVT), ventricular tachycardia (VT), or ventricular fibrillation (VF). A participant meets the endpoint upon documentation of any component and is counted once, even if multiple components or episodes occur. Medical intervention is not required. Counts will be compared between study groups.

Throughout the planned 36-month participant follow-up period.
Number of participants who die from any cause
Prazo: Throughout the planned 36-month participant follow-up period.

Number of participants who die from any cause during follow-up, compared between the ICM and standard-care groups.

Throughout the planned 36-month participant follow-up period.
Number of participants who die from a cardiovascular cause
Prazo: Throughout the planned 36-month participant follow-up period.

Number of participants who die as a result of a cardiovascular complication, as defined in the protocol, compared between the ICM and standard-care groups.

Throughout the planned 36-month participant follow-up period.
Number of participants with a documented cardiac arrhythmia
Prazo: Throughout the planned 36-month participant follow-up period.

Composite endpoint comprising documented cardiac arrhythmias as defined in the protocol. A participant is counted once upon documentation of any qualifying arrhythmia, regardless of the number or type of subsequent arrhythmias. Medical intervention is not required. Counts will be compared between study groups.

Throughout the planned 36-month participant follow-up period.
Number of participants with documented bradycardia
Prazo: Throughout the planned 36-month participant follow-up period.

Number of participants with at least one documented episode of bradycardia meeting the protocol definition. Each participant is counted once. Counts will be reported by study group and according to whether bradycardia prompts medical intervention.

Throughout the planned 36-month participant follow-up period.
Number of participants with documented sinus node dysfunction
Prazo: Throughout the planned 36-month participant follow-up period.

Number of participants with documented sinus node dysfunction. Each participant is counted once. Counts will be reported by study group and according to whether sinus node dysfunction prompts medical intervention.

Throughout the planned 36-month participant follow-up period.
Number of participants with documented atrioventricular block
Prazo: Throughout the planned 36-month participant follow-up period.

Number of participants with documented atrioventricular block, classified using the protocol definitions. Each participant is counted once. Counts will be reported by study group and according to whether atrioventricular block prompts medical intervention.

Throughout the planned 36-month participant follow-up period.
Number of participants with documented atrial fibrillation
Prazo: Throughout the planned 36-month participant follow-up period.

Number of participants with documented atrial fibrillation meeting the protocol definition. Each participant is counted once. Counts will be reported by study group and according to whether atrial fibrillation prompts medical intervention.

Throughout the planned 36-month participant follow-up period.
Number of participants with documented supraventricular tachycardia other than atrial fibrillation
Prazo: Throughout the planned 36-month participant follow-up period.

Number of participants with documented supraventricular tachycardia other than atrial fibrillation, classified using the protocol definitions. Each participant is counted once. Counts will be reported by study group and according to whether the arrhythmia prompts medical intervention.

Throughout the planned 36-month participant follow-up period.
Number of participants with documented non-sustained ventricular tachycardia
Prazo: Throughout the planned 36-month participant follow-up period.

Number of participants with documented non-sustained ventricular tachycardia (NSVT) meeting the protocol definition. Each participant is counted once. Counts will be reported by study group and according to whether NSVT prompts medical intervention.

Throughout the planned 36-month participant follow-up period.
Number of participants with documented ventricular tachycardia
Prazo: Throughout the planned 36-month participant follow-up period.

Number of participants with documented ventricular tachycardia (VT) meeting the protocol definition. Each participant is counted once. Counts will be reported by study group and according to whether VT prompts medical intervention.

Throughout the planned 36-month participant follow-up period.
Number of participants with documented ventricular fibrillation
Prazo: Throughout the planned 36-month participant follow-up period.

Number of participants with documented ventricular fibrillation (VF) meeting the protocol definition. Each participant is counted once. Counts will be reported by study group and according to whether VF prompts medical intervention.

Throughout the planned 36-month participant follow-up period.
Number of participants receiving invasive interventions for cardiac arrhythmias
Prazo: Throughout the planned 36-month participant follow-up period.

Number of participants receiving at least one invasive clinical intervention for a documented cardiac arrhythmia. Each participant is counted once, regardless of the number of invasive interventions received. Counts will be compared between study groups.

Throughout the planned 36-month participant follow-up period.
Number of participants with supraventricular arrhythmias necessitating clinical intervention
Prazo: Throughout the planned 36-month participant follow-up period.

Number of participants with at least one documented supraventricular arrhythmia that prompts clinical intervention. Each participant is counted once. Counts will be compared between the ICM and standard-care groups.

Throughout the planned 36-month participant follow-up period.
Number of participants with bradycardia necessitating clinical intervention
Prazo: Throughout the planned 36-month participant follow-up period.

Number of participants with at least one documented episode of bradycardia that prompts clinical intervention. Each participant is counted once. Counts will be compared between the ICM and standard-care groups.

Throughout the planned 36-month participant follow-up period.
Number of participants with ventricular arrhythmias necessitating clinical intervention
Prazo: Throughout the planned 36-month participant follow-up period.

Number of participants with at least one documented ventricular arrhythmia that prompts clinical intervention. Each participant is counted once. Counts will be compared between the ICM and standard-care groups.

Throughout the planned 36-month participant follow-up period.
Number of participants receiving an implantable cardioverter-defibrillator
Prazo: Throughout the planned 36-month participant follow-up period.

Number of participants undergoing implantable cardioverter-defibrillator (ICD) implantation during follow-up. Each participant is counted once. Counts will be compared between study groups.

Throughout the planned 36-month participant follow-up period.
Number of participants receiving a pacemaker
Prazo: Throughout the planned 36-month participant follow-up period.

Number of participants undergoing pacemaker implantation during follow-up. Each participant is counted once. Counts will be compared between study groups.

Throughout the planned 36-month participant follow-up period.
Number of participants receiving appropriate implantable cardioverter-defibrillator therapy
Prazo: From ICD implantation through the end of the planned 36-month participant follow-up period.

Number of participants receiving at least one appropriate implantable cardioverter-defibrillator (ICD) therapy after ICD implantation. Each participant is counted once, regardless of the number of appropriate therapies received.

From ICD implantation through the end of the planned 36-month participant follow-up period.
Number of participants with complications related to insertable cardiac monitor implantation
Prazo: From ICM implantation through the end of ICM follow-up, anticipated to last 36 months after implantation.

Number of participants in the ICM group experiencing at least one complication related to ICM implantation, including implantation-site infection, hematoma, or device migration. Each participant is counted once. Complication types will be reported as categories of the same participant-count measure.

From ICM implantation through the end of ICM follow-up, anticipated to last 36 months after implantation.
Number of participants with suspected serious complications related to arrhythmia-directed clinical interventions
Prazo: Throughout the planned 36-month participant follow-up period.

Number of participants experiencing at least one suspected serious complication related to a clinical intervention performed for a detected cardiac arrhythmia. Each participant is counted once. Complication types will be reported as categories of the same participant-count measure.

Throughout the planned 36-month participant follow-up period.
Number of participants meeting the composite health-risk endpoint
Prazo: Clinical events throughout the planned 36-month follow-up period; NYHA class assessed at baseline and 12, 24, and 36 months.

Composite endpoint comprising an increase of at least one NYHA class, heart failure admission, cardiovascular death, percutaneous coronary intervention, myocardial infarction, cerebrovascular accident, coronary artery bypass grafting, or valve surgery. A participant meets the endpoint if any component occurs and is counted once, regardless of the number of components experienced. Counts will be compared between study groups.

Clinical events throughout the planned 36-month follow-up period; NYHA class assessed at baseline and 12, 24, and 36 months.
Percentage of participants with documented non-sustained ventricular tachycardia
Prazo: During the first 30 days and first 6 months after initiation of LUX monitoring.

Percentage of participants in the insertable cardiac monitor (ICM) group with at least one adjudicated non-sustained ventricular tachycardia (NSVT) episode during each assessment window. Each participant is counted once per window, regardless of the number of episodes. The percentage is calculated as the number of participants with NSVT divided by the number of participants in the analysis population, multiplied by 100. The numerator and denominator will also be reported.

During the first 30 days and first 6 months after initiation of LUX monitoring.
Rate of non-sustained ventricular tachycardia episodes per monitoring day
Prazo: During the first 30 days and first 6 months after initiation of LUX monitoring.

Rate of all adjudicated non-sustained ventricular tachycardia (NSVT) episodes recorded by the insertable cardiac monitor (ICM). All qualifying episodes are counted, including recurrent episodes within the same participant. For each assessment window, the rate is calculated as the total number of NSVT episodes across participants in the ICM group divided by their total observed ICM monitoring time in days. NSVT is classified according to the protocol definition.

During the first 30 days and first 6 months after initiation of LUX monitoring.
Percentage of participants with documented sustained ventricular tachycardia
Prazo: During the first 30 days and first 6 months after initiation of LUX monitoring.

Percentage of participants in the ICM group with at least one adjudicated sustained ventricular tachycardia (VT) episode during each assessment window. Each participant is counted once per window. The percentage is calculated as the number of participants with sustained VT divided by the number of participants in the analysis population, multiplied by 100. The numerator and denominator will also be reported.

During the first 30 days and first 6 months after initiation of LUX monitoring.
Rate of documented sustained ventricular tachycardia episodes per monitoring day
Prazo: During the first 30 days and first 6 months after initiation of LUX monitoring

Rate of all adjudicated sustained VT episodes recorded by the ICM, including recurrent episodes within the same participant. For each assessment window, the rate is calculated as the total number of sustained VT episodes across participants in the ICM group divided by their total observed ICM monitoring time in days. Results are expressed as sustained VT episodes per monitoring day.

During the first 30 days and first 6 months after initiation of LUX monitoring
Percentage of participants meeting the early composite PVC, NSVT, VT, or VF endpoin
Prazo: During the first 30 days and first 6 months of participant follow-up.

Percentage of participants meeting a composite endpoint comprising PVC, NSVT, sustained VT, or ventricular fibrillation (VF). A participant meets the endpoint if any component occurs and is counted once per assessment window. The percentage is calculated as the number of qualifying participants divided by the number in the analysis population, multiplied by 100, and compared between study groups.

During the first 30 days and first 6 months of participant follow-up.
Rate of events meeting the early composite PVC, NSVT, VT, or VF endpoint
Prazo: During the first 30 days and first 6 months of participant follow-up.

Rate of events meeting the composite endpoint comprising PVC, NSVT, sustained VT, or VF. Qualifying events will be counted according to protocol description and divided by time of follow-up. Results will be compared between study groups.

During the first 30 days and first 6 months of participant follow-up.
Mean premature ventricular contraction burden
Prazo: Throughout ICM monitoring, anticipated to last 36 months after implantation.

Mean premature ventricular contraction (PVC) burden recorded by the ICM in the ICM group. For each participant, daily device-recorded PVC burden, expressed as a percentage, will be averaged over the observation period. The participant-level averages will then be summarized as the group mean PVC burden

Throughout ICM monitoring, anticipated to last 36 months after implantation.
Change from baseline in EQ-5D-5L score
Prazo: Baseline and 12, 24, and 36 months. Follow-up questionnaires are completed within 1 month of each scheduled assessment.

Health status assessed using the EQ-5D-5L specific score. Changes from baseline will be calculated at 12, 24, and 36 months and compared between the ICM and standard-care groups to assess differences in change over time. There is also an visual analogue sclae with scores that ranges from 0 to 100, with higher scores indicating better perception of being healthy. Changes will be summarized using these scores

Baseline and 12, 24, and 36 months. Follow-up questionnaires are completed within 1 month of each scheduled assessment.
Change from baseline in self-assessed NYHA class
Prazo: Baseline and 12, 24, and 36 months. Follow-up questionnaires are completed within 1 month of each scheduled assessment.

Functional status assessed using self-assessed New York Heart Association (NYHA) class. Changes from baseline will be determined at 12, 24, and 36 months and compared between the ICM and standard-care groups. Changes will be reported as NYHA class. Higher NYHA classes indicate greater functional limitation.

Baseline and 12, 24, and 36 months. Follow-up questionnaires are completed within 1 month of each scheduled assessment.
Change from the initial post-implant assessment in Florida Patient Acceptance Survey using the FPAS specific score
Prazo: Baseline and 12, 24, and 36 months. Follow-up questionnaires are completed within 1 month of each scheduled assessment.

Device acceptance assessed using the Florida Patient Acceptance Survey (FPAS) in the ICM group only. Changes from the initial post-implant assessment will be calculated at 12, 24, and 36 months to assess change over time. The score ranges from 0 to 100, with higher scores indicating better acceptance.

Baseline and 12, 24, and 36 months. Follow-up questionnaires are completed within 1 month of each scheduled assessment.
NT-proBNP concentration
Prazo: Baseline: within 6 months before enrollment and after the most recent MI. Additional routine-care measurements throughout the planned 36-month follow-up.

NT-proBNP concentration measured in blood samples and expressed in ng/L. Baseline concentrations will be evaluated as a predictor of cardiac arrhythmias. Follow-up concentrations will be collected only when measured during routine clinical care.

Baseline: within 6 months before enrollment and after the most recent MI. Additional routine-care measurements throughout the planned 36-month follow-up.

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Mean daily coffee intake assessed using the study questionnaire
Prazo: At baseline, 12-, 24-, and 36 months

Participant-reported coffee intake assessed using the additional study questionnaire and expressed as cups per day. The mean number of cups consumed per day will be calculated across participants with available questionnaire responses at each assessment.

At baseline, 12-, 24-, and 36 months
Mean weekly alcohol intake assessed using the study questionnaire
Prazo: At baseline, 12-, 24-, and 36 months

Participant-reported alcohol intake assessed using the additional study questionnaire and expressed as standard drinks per week. Mean weekly intake will be calculated across participants with available questionnaire responses at each assessment.

At baseline, 12-, 24-, and 36 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Reinoud E Knops, Prof, MD, PhD, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

17 de abril de 2026

Conclusão Primária (Estimado)

1 de abril de 2030

Conclusão do estudo (Estimado)

1 de abril de 2031

Datas de inscrição no estudo

Enviado pela primeira vez

20 de outubro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

10 de novembro de 2026

Primeira postagem (Real)

17 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

17 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

10 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • NL-010971

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever